Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2011. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of a specific share transaction rather than a financial performance report.
Material Changes
The filing reports a transaction on October 11, 2011, involving Mr. D E Troy. His interest in Ordinary share ADRs increased to 282,884 units. This increase resulted from the re-investment of the dividend paid to shareholders on October 6, 2011, at a price of $42.37 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of ADRs held by Mr. D E Troy following the dividend re-investment (282,884).
- Confirm the transaction price of $42.37 per ADR used for the dividend re-investment.
- Note that this filing does not contain updated financial performance data for the period.